Thrombolytics for PE?

By  |  November 14, 2008 | 

It is clear that patients with stable PE should not be treated with thrombolytics (ACCP guidelines). However, in those that are “unstable” it is less clear when to administer it. In a past small RCT in patients with submassive PE (defined as R heart dysfunction or pulmonary HTN) (abstract) anteplase+heparin (versus heparin) reduced clinical deterioration of PE patients, but not death or recurrent PE. In this retrospective cohort of over 15,000 patients, thrombolytics were given to only 2.4% of patients. Using propensity scoring, they found higher mortality in those given thrombolytics, but no difference in death in the high-propensity scorers with or without thrombolytics. Although this study was imperfect with residual confounding, it does suggest a few things: we are appropriately stingy in giving thrombolytics (<3%), the risk of bleeding is low (2%), the risk of death is high (10%), and it is still up to us to imperfectly determine which patients are “unstable” and will therefore more likely benefit from thrombolytics  (abstract) (editorial)

Leave A Comment

About the Author:

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.


Related Posts

By  | July 2, 2015 |  0
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
By  | September 8, 2014 |  3
  As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
By  | July 6, 2013 |  0
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]